Ruxolitinib (NCT07228624)

Name: Ruxolitinib trial for Myelodysplastic/Myeloproliferative Neoplasm (NCT07228624)
Uploaded: 2026-10-31T22:10:58.138Z
Duration: 1 min 28 s
Description: Ruxolitinib trial for Myelodysplastic/Myeloproliferative Neoplasm (NCT07228624). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07228624.

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: a one-minute explainerNCT072286241 min

Ruxolitinib trial for Myelodysplastic/Myeloproliferative Neoplasm (NCT07228624). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with myelofibrosis or myelodysplastic/myeloproliferative overlap syndromes who qualify for donor transplantation. Age is usually 18–75; selected older patients may qualify. Leukemic transformation and prior donor transplantation are excluded.

The idea: use a JAK inhibitor before transplant, then ruxolitinib through transplantation and afterward. Ruxolitinib blocks growth and immune signals. Chemotherapy, donor stem cells, tacrolimus and methotrexate are also given. Researchers assess graft-versus-host disease. Ruxolitinib continues 12 months, then tapers over six.

This phase 2 study plans 50 patients. Rachel Salit leads in Seattle, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.